TABLE 2.

Influence of NAFLD on the severe event in subgroups of COVID‐19 patients according to gender, age, BMI and comorbidities

	Severe event (n, %)		p value	Virus shedding time (days)		p value	Length of hospital stay (days)		p value
	NAFLD (n=86)	Non‐NAFLD (n = 132)		NAFLD (n=86)	Non‐NAFLD (n = 130)		NAFLD (n=86)	Non‐NAFLD (n = 130)
Gender
Male	12 (23.1%)	13 (22.4%)	0.934	17 (6–47)	17.5 (6–42)	0.696	14 (5–41)	17 (5–37)	0.689
Female	7 (20.6%)	9 (12.2%)	0.252	17.5 (1–38)	19 (5–53)	0.131	17 (5–37)	16 (5–40)	0.569
Age
Elderly (≥ 60 years)	5 (25%)	13 (35.1%)	0.432	16 (4–38)	23 (11–43)	0.011	17 (6–37)	21 (6–40)	0.155
Non‐elderly (< 60years)	14 (21.2%)	9 (10.5%)	0.036	17.5 (3–47)	17 (6–53)	0.975	15 (5–41)	15 (5–40)	0.986
BMI
BMI ≥24 kg/m2	7 (14.6%)	7 (23.3%)	0.327	18.5 (8–47)	21 (6–45)	0.595	15 (5–41)	17 (6–40)	0.643
18.5 ≤ BMI <24 kg/m2	9 (30%)	9 (11.5%)	0.021	17 (3–38)	17 (8–53)	0.939	16.5 (5–37)	16 (5–37)	0.697
BMI <18.5 kg/m2	NA	3 (21.4%)	NA	NA	18.5 (8–40)	NA	NA	14.5 (8–40)	NA
Hypertension
Yes	9 (45%)	4 (33.3%)	0.780	16.5 (11–45)	18 (12–43)	0.366	16.5 (5–41)	21 (8–35)	0.387
No	10 (15.2%)	18 (15.0%)	0.978	17.5 (3–47)	18.5 (6–53)	0.138	16.5 (11–45)	18 (12–43)	0.348
Cardiovascular disease
Yes	2 (66.7%)	2 (40.0%)	1.000	21 (19–29)	35 (22–29)	0.114	22 (19–27)	24.5 (14–35)	0.857
No	17 (20.5%)	20 (15.7%)	0.379	17 (3–47)	18 (6–53)	0.205	15 (5–41)	16 (5–40)	0.411
Diabetes
Yes	2 (22.2%)	2 (40.0%)	0.580	15 (9–29)	27 (15–43)	0.112	15 (6–30)	28 (17–32)	0.060
No	17 (22.1%)	20 (15.7)	0.255	17 (3–47)	18 (6–53)	0.259	15 (5–41)	16 (5–40)	0.560
Chronic liver disease
Yes	2 (40.0%)	1 (16.7%)	0.545	16 (14–29)	24 (11–34)	0.537	13 (9–27)	22 (8–36)	0.662
No	17 (21.0%)	21 (16.7%)	0.433	17 (3–47)	18 (6–53)	0.188	15 (5–41)	15 (5–40)	0.496

Abbreviations: NAFLD, Non‐alcohol fatty liver disease; BMI, Body mass index; NA, Not available.